Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Cerilliant
Express Scripts
Fuji
Queensland Health
McKinsey
Chubb
Medtronic

Generated: July 20, 2018

DrugPatentWatch Database Preview

UROXATRAL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Uroxatral, and when can generic versions of Uroxatral launch?

Uroxatral is a drug marketed by Concordia Pharms Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in thirty-eight countries.

The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.
Drug patent expirations by year for UROXATRAL
Pharmacology for UROXATRAL
Synonyms for UROXATRAL
(+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride
133880-44-1
2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, monohydrochloride (+-)-
4-Amino-6,7-dimethoxy-2-[methyl[3-[(tetrahydro-2-furoyl)amino]propyl]amino]quinazoline Hydrochloride
403A681
81403-68-1
81403-80-7 (Parent)
AB0008072
AB2000094
AC-1116
AC1L2GRP
AC1Q5PED
AKOS015966770
Alfetim
Alfoten
Alfuzosin (hydrochloride)
Alfuzosin for peak identification, European Pharmacopoeia (EP) Reference Standard
Alfuzosin for system suitability A, European Pharmacopoeia (EP) Reference Standard
Alfuzosin for system suitability, European Pharmacopoeia (EP) Reference Standard
Alfuzosin HCl
Alfuzosin Hydrochloride
Alfuzosin hydrochloride (JAN/USAN)
Alfuzosin hydrochloride (Uroxatral)
Alfuzosin hydrochloride [USAN:USP]
Alfuzosin hydrochloride [USAN]
Alfuzosin hydrochloride, >=98% (HPLC), solid
Alfuzosin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Alfuzosin hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur
Alfuzosin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Alfuzosin hydrochloride;
API0001407
AS-14240
AT-12271
BC677639
BCP9000271
BCPP000417
C19H27N5O4
C19H28ClN5O4
CAS-81403-68-1
CC-23835
CCG-213373
CHEBI:32286
CHEMBL1723
CS-2087
CTK8F7637
D01692
D0H1YQ
DSSTox_CID_25514
DSSTox_GSID_45514
DSSTox_RID_80924
DTXSID3045514
FT-0630890
HMS1569A05
HY-B0192A
K448
KS-00000XK8
LP00224
LS-70107
MFCD00879135
MolPort-006-391-851
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide hydrochloride
N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl]tetrahydro-2-furancarboxamide Hydrochloride
n-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride
N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolynyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride
N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride
n-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid
NCGC00016946-01
NCGC00095152-09
NCGC00260909-01
s1409
SCHEMBL179910
SL 77 499-10
SL 77499-10
SL-77.0499-10
SL-77499
SL-77499-10
SL-7749910
Tox21_110701
Tox21_110701_1
Tox21_500224
Urion
Uroxatral (TN)
Uroxatral hydrochloride
Uroxatral, Alfuzosin hydrochloride
Xatral
Xatral OD
Xatral Retard
Xatral SR
Xatral XL
YTNKWDJILNVLGX-UHFFFAOYSA-N

US Patents and Regulatory Information for UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Concordia Pharms Inc UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for UROXATRAL
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 10 mg ➤ Subscribe ➤ Try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Julphar
Teva
Harvard Business School
Cipla
US Army
Fuji
Accenture
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.